Clinical Trial Update: TARC After alloSCT in Hodgkin's Lymphoma

View source ↗

Summary

This clinical trial update notes the completion of a study evaluating TARC levels after allogeneic stem cell transplantation in patients with Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation | Status: COMPLETED